One of my preferred simple stock investing techniques for individual investors is to put your retirement wealth in a growing stock. That sounds pretty simple, but many investors quickly understand it’s not as simple an investing plan as it appears — particularly when it arrives to finding hot penny stocks to buy now. After all, many of the big-name shares to purchase that you hear about every day are massive blue chips that have already seen their biggest development. And some of the penny stocks that are small up-and-comers are aggressive, risky investments that could cost you everything.
So how do you find emergent stocks — and specially for smaller investors, the best penny stocks to buy? My advice to you is to look closely at the figures. That means taking a hard look at earnings, sales and estimates for each investment you think is worthy of your retirement money.
Antares Pharma Inc. (AIS) invites particular attention in this matter. This pharmaceutical company, focuses on self-injection pharmaceutical products and technologies, and topical gel-based products. It offers injection devices, which include Medi-Jector Vision for insulin; Zomajet 2 Vision, Zomajet Vision X, Twin-Jector EZ II, and Tjet for human growth hormone; Vibex pressure assisted auto injector platform that enables a controlled pressure delivery of drugs into the body utilizing a spring power source; and disposable pen injectors, which are needle-based devices designed to deliver multiple injections from multi-dose drug cartridges. The company also develops/commercializes Anturol, an oxybutynin ATD (advanced transdermal delivery)gel, which is in Phase III clinical trials for the treatment of overactive bladder; Elestrin, a transdermal estradiol gel for the treatment of moderate-to-severe vasomotor symptoms associated with menopause; LibiGel, a transdermal testosterone gel that is in Phase III clinical studies for the treatment of female sexual dysfunction; Nestorone contraceptive formulation products, which has completed Phase II clinical trials; and Ropinerole to treat a central nervous system. Antares Pharma, Inc. markets its products to pharmaceutical companies primarily in the United States and Europe.
Though the company is not yet profitable, it has lessened its loss in each of the last three quarters and has met or exceeded Wall Street expectations in each of these intervals. That’s a sign of positive momentum for this penny stock. Also worth noting is that investors everywhere have been snatching up AIS stock — with shares up a whopping 57% year-to-date!